This is the authors' abstract. We don't add key points for this paper.
Five cases of bacterial meningitis treated with ceftaroline (4 Streptococcus pneumoniae and 1 Staphylococcus aureus) are summarized here. The pharmacodynamics of human cathelicidin LL-37 and ceftaroline were evaluated against S. pneumoniae. Patients who received ceftaroline 600 mg every 8 h (q8h) (1 S. aureus and 3 S. pneumoniae) were successfully treated; treatment failed in 1 patient with S. pneumoniae who received 600 mg q12h. Ceftaroline increased the negative surface charge and sensitized S. pneumoniae to killing by LL-37, a peptide implicated in blood-brain barrier defense.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sakoulas et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: